Aarti Pharmalabs Limited has informed the Exchange that Board of Directors at its meeting held on May 25, 2026, recommended Final Dividend of Rs. 2 per equity share.
AARTIPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.8 pts less than Nifty Microcap 250 and 5.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Aarti Pharmalabs Limited reported FY26 standalone revenue of Rs. 179,755 lakhs, marginally higher than Rs. 177,135 lakhs in FY25. However, standalone PAT declined significantly to Rs. 17,620 lakhs from Rs. 25,735 lakhs in FY25, a drop of about 31.5%. The board recommended a final dividend of Rs. 2 per share (40% on Rs. 5 face value), subject to shareholder approval. An exceptional item of Rs. 279.49 lakhs was recognized for new labour code provisions. The auditors issued an unmodified (clean) opinion but included an Emphasis of Matter paragraph regarding a foreign exchange derivative contract that was inadvertently excluded from fair value calculations in FY24-25, requiring restatement of Q3 FY26 comparative figures.
The significant PAT decline despite flat revenue suggests margin compression due to higher material costs, finance costs, and foreign exchange losses. The dividend declaration provides some positive signal for shareholders, but the restatement and profit decline may create near-term concerns for investors.